The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis Patients
Received Date: Mar 23, 2016 / Accepted Date: Apr 25, 2016 / Published Date: Apr 29, 2016
Variations of clinical response of cyclophosphamide (CTX) treatment in lupus nephritis (LN) could still be recognized. LN patients with a GSTA1mutation (CT heterozygous) had a risk of none-response (P=0.005). Pharmacokinetics data indicated that patients with a GSTA1 heterozygous variant had a lower exposure to 4-OHCTX compared to wild-type patients (P=0.023). And clinical efficacy was significantly related to higher exposure to 4- OH-CTX (P=0.038). In conclusion, LN patients with GSTA1 heterozygousgenotypes had poor CTX treatment response due to less exposure to activated 4-OH-CTX.
Keywords: Lupus nephritis; Nephrology; Cyclophosphamide; GSTA1; Pharmacokinetics; Pharmacogenomics
Citation: Wang NH, Zhu XY, Zhu Y, Zhao M, Chen YC, et al. (2016) The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis Patients. Lupus Open Access 1: 115.
Copyright: © 2016 Wang HN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
April 19-20, 2018 Amsterdam, Netherlands
May 11-12, 2018 Osaka, Japan
August 06-07, 2018 Dubai, UAE
September 13-14, 2018 Zurich, Switzerland
- Total views: 8116
- [From(publication date): 7-2016 - Dec 18, 2017]
- Breakdown by view type
- HTML page views: 8049
- PDF downloads: 67